Apoio Takeda

Apoio Gedii

ECCO 2019 - edifíciosECCO 2019 - data

Best practice in UC

Andre D’Hoore, Leuven, Belgium

Henit Yanai, Petah Tikva, Israel

When do you start a biologic?

OP09: Histological remission and mucosal healing in a randomised, placebo-controlled, phase 2 study of etrasimod in patients with Moderately to Severely Active Ulcerative Colitis

OP10: Systems genomics of Ulcerative Colitis: Combining GWAS and signalling networks for patient stratification and individualised drug targeting in Ulcerative Colitis

OP11: Organoids derived from inflamed intestinal biopsies of patients with Ulcerative Colitis lose their inflammatory phenotype during ex vivo culture

Where is the exit?

OP12: Targeting inflammation in Ulcerative Colitis by inhibiting glucose uptake

OP13: Molecular response to ustekinumab in Moderate to Severe Ulcerative Colitis by serum protein and biopsy gene expression analysis: Results from the UNIFI phase 3 induction study

OP14: Improved endoscopic outcomes and mucosal healing of upadacitinib as an induction therapy in adults with Moderately to Severely Active Ulcerative Colitis: Data from the U-ACHIEVE study

Precision surgery in UC

Informação Adicional

  • Data de Início: sexta-feira, 08 março 2019
  • Data de Fim: segunda-feira, 04 março 2019
  • Horário: 08:30-10:30
  • Localidade: Plenary Hall, Hall A, Bella Center

Subscrever Newsletter do Congresso


HB4 M1-2, Bella Center
08:00- 11:30
Auditorium 15, Hall A, Bella Center
Plenary Hall, Hall A, Bella Center
Plenary Hall, Hall A, Bella Center

Área Reservada